FINWIRES · TerminalLIVE
FINWIRES

Canada Goose Unlikely to See Meaninful Upside in Coming Quarters, UBS Says

By

Canada Goose (GOOS) may struggle to generate meaningful upside in the coming quarters as weak revenue growth and macro uncertainty continue to cloud the outlook, UBS said in a note emailed Friday.

The brokerage said it sees "few catalysts ahead" for the stock, noting that investors are unlikely to get major new data points before the company's fiscal Q2 report later this year because of the seasonal nature of the business.

UBS added that North American traffic remains choppy, while Europe could face pressure from slowing tourist demand.

At the same time, UBS said Canada Goose is making progress in areas including wholesale execution, store operations and merchandising.

UBS maintained its fiscal 2027 to 2029 earnings estimates, saying the company can still gradually improve margins over the longer term as it expands internationally and grows newer categories.

UBS maintained its neutral rating and $12 price target.

Price: $9.68, Change: $-0.21, Percent Change: -2.12%

Related Articles

Australia

Optimum Communications Shares Fall After Citigroup Downgrade

Optimum Communications (OPTU) shares were down nearly 10% in recent Friday trading after Citigroup downgraded the telecommunications provider to sell from neutral and cut its price target to $0.50 from $1.50.Trading volume stood at about 3.5 million shares compared with a daily average of nearly 2.8 million shares.Price: $0.79, Change: $-0.09, Percent Change: -9.87%

$OPTU
Australia

Celsius on Strong Long-Term Growth Path Despite Recent Slowdown, UBS Says

Celsius (CELH) appears to have a strong long-term growth trajectory despite slowing beverage sales in recent months, UBS said in a note emailed Friday.The company continues to benefit from growth in household penetration and purchase rate as its distribution agreement with PepsiCo (PEP) nears four years, the firm said. The brand has faced growth across most demographics, with expectations of gaining more shelf space in 2026 amid product launches such as the new energy drink Electric Vibe, according to the note.The investment firm, however, noted that Celsius has experienced sluggish sales since December due to increasing competition and weakness in certain products.UBS added that given the volatility, investors are likely to take a "wait and see approach" toward the stock, but over the long term, the potential upside outweighs the downside risk with the weakness looking "overdone."UBS maintained its buy rating and price target of $55.Price: $30.03, Change: $+1.02, Percent Change: +3.52%

$CELH$PEP
Australia

Update: Sutro Biopharma Shares Rise After Q1 Loss Narrows

(Updates with the company's stock move in the headline and in the first paragraph, cash runway estimate in the sixth paragraph, Wedbush upgrade in the seventh paragraph.)Sutro Biopharma (STRO) shares were up 1.9% in Friday trading after the company reported a narrower Q1 loss late Thursday.The company posted a quarterly loss of $2.94 per diluted share, narrowing from a loss of $9.08 a year earlier.Analysts surveyed by FactSet expected a loss of $2.74.Revenue for the three months ended March 31 was $14.5 million, down from $17.4 million a year earlier.Analysts polled by FactSet expected $8.9 million.Sutro Biopharma said that its cash runway is now expected into at least Q2 of 2028, excluding additional anticipated milestones from its existing collaborations.Wedbush upgraded its rating on the company's stock to outperform from neutral and raised its price target to $60 from $22.Price: $39.31, Change: $+0.89, Percent Change: +2.32%

$STRO